Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
Open Access
- 29 June 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13), 2879
- https://doi.org/10.3390/jcm10132879
Abstract
Background: Extremes of body weight may alter exposure to non-vitamin K antagonist oral anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis assessed 1-year outcomes in routine care patients with atrial fibrillation across a range of body weight groups treated with edoxaban. Methods: ETNA-AF-Europe is a multinational, multicentre, observational study conducted in 825 sites in 10 European countries. Overall, 1310, 5565, 4346 and 1446 enrolled patients were categorised into ≤60 kg, >60–≤80 kg (reference weight group), >80–≤100 kg and >100 kg groups. Results: Patients weighing ≤60 kg were older, more frail and had a higher CHA2DS2-VASc score vs. the other weight groups. The rates of stroke/systemic embolism, major bleeding and ICH were low at 1 year (0.82, 1.05 and 0.24%/year), with no significant differences among weight groups. The annualised event rates of all-cause death were 3.50%/year in the overall population. After adjustment for eGFR and CHA2DS2-VASc score, the risk of all-cause death was significantly higher in extreme weight groups vs. the reference group. Conclusions: Low rates of stroke and bleeding were reported with edoxaban, independent of weight. The risk of all-cause death was higher in extremes of weight vs. the reference group after adjustment for important risk modifiers, thus no obesity paradox was observed.This publication has 46 references indexed in Scilit:
- Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?Stroke, 2017
- Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomesScientific Reports, 2016
- Association of Body Mass Index With Care and Outcomes in Patients With Atrial FibrillationJACC: Clinical Electrophysiology, 2016
- The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trialEuropean Heart Journal, 2016
- Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Monitoring Individual Wave Characteristics in the Inner Surf with a 2-Dimensional Laser Scanner (LiDAR)Journal of Sensors, 2016
- Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor XaClinical Pharmacokinetics, 2015
- Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and linksJournal of Cardiology, 2015
- Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyEP Europace, 2015
- Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial FibrillationCirculation Journal, 2012